Methods Of Treating Fabry Patients Having Renal Impairment
AssigneeAmicus Therapeutics, Inc.
InventorsJeff Castelli, Elfrida Benjamin
Life of this patent
Estimating the term…
Abstract
Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
Claims1
A method of treating Fabry disease in an enzyme replacement therapy (ERT)-experienced patient diagnosed with Fabry disease and having mild renal impairment, the method comprising administering to the patient an effective amount of the migalastat or salt thereof at a frequency of once every other day, wherein the effective amount is 100 mg to 150 mg free base equivalent (FBE).
Dependencies are inferred from the claim text.